{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a palmitate
to a specific field?
Status:
Investigational
Source:
NCT02983617: Phase 2 Interventional Completed Chronic Lymphocytic Leukemia
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Entospletinib (GS-9973) is an adenosine triphosphate competitive inhibitor of Syk that disrupts kinase activity, which is currently in clinical trials for multiple B-cell malignancies. The most common treatment-emergent serious adverse events included dyspnea, pneumonia, febrile neutropenia, dehydration, and pyrexia.
Status:
Investigational
Source:
NCT03257592: Phase 1 Interventional Terminated Schizophrenia
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:remeglurant [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Remeglurant is a selective antagonist of subtype 5 metabotropic glutamate receptors (mGluR5). mGluR5 antagonists have a modulatory role in the control of glutamatergic neurotransmission. This drug was developed for treatment in drug-induced dyskinesia (an involuntary movement disorder). A phase 1 trial was conducted but no further development has been reported since 2016.
Status:
Investigational
Source:
NCT00398125: Phase 2 Interventional Completed Infection, Human Immunodeficiency Virus
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
GlaxoSmithKline was developing GSK-364735 as a human immunodeficiency virus (HIV) integrase inhibitor. The inhibition of viral DNA integration takes place by interacting at the two-metal binding site within the catalytic center of HIV integrase. GSK-364735 was successfully studied at Phase II in HIV-infected patients; however, adverse liver effects of GSK364735 were recently observed in a long-term preclinical safety study in the monkey and preclude further development of the compound.
Status:
Investigational
Source:
NCT03519230: Phase 3 Interventional Active, not recruiting Ovarian Cancer
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04564703: Phase 2 Interventional Active, not recruiting Multiple Myeloma
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
CC-220 is a potent cereblon modulating agent that displays anti-proliferative, pro-apoptotic and immunomodulatory activity on sensitive and resistant multiple myeloma cell lines. CC-220 is currently under clinical investigation for systemic lupus erythematosus and multiple myeloma as a single agent, or in combination with dexamethasone in patients who may have previously been exposed to pomalidomide. Comparable to other Cereblon-binding agents, ex vivo treatment of CC-220 on B-cells, T-cells, and monocytes leads to the degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). followed by disruption of the multiple myeloma promoting c-Myc/IRF4 axis.
Status:
Investigational
Source:
NCT01538420: Phase 1 Interventional Completed Healthy
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
GLPG-0492, an orally available selective androgen receptor modulator (SARM) was tested in a Phase I Proof of Mechanism study to assess the effect on muscle function in healthy volunteers. A biomarker effect similar to that of Oxandrolone was observed, but the data were insufficient for Galapagos to pursue GLPG-0492 further in cachexia, and further development of the compound was discontinued. GLPG-0492 is currently under development for musculo-skeletal diseases such as sarcopenia and Duchenne muscular dystrophy.
Status:
Investigational
Source:
NCT01490086: Phase 2 Interventional Completed Acute Schizophrenia
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00333411: Phase 2 Interventional Completed Psoriasis
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04668235: Phase 3 Interventional Completed COVID-19
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
